DAX24.065 -0,8%ESt505.320 -1,4%Top 10 Crypto16,00 -0,3%Dow44.131 -0,7%Nas21.122 ±-0,0%Bitcoin101.751 -1,3%Euro1,1419 ±0,0%Öl72,55 -1,3%Gold3.290 ±-0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Microsoft 870747 Rheinmetall 703000 adidas A1EWWW Heidelberger Druckmaschinen 731400 Lufthansa 823212 Meta Platforms (ex Facebook) A1JWVX DroneShield A2DMAA Siemens Energy ENER6Y BYD A0M4W9 Amazon 906866 Commerzbank CBK100 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Wall Street letztlich tiefer -- DAX schließt in Rot -- Figma-IPO -- HENSOLDT wächst weiter kräftig -- BMW, Airbus, AMD, Novo Nordisk, PayPal, D-Wave, BYD, DroneShield, Bayer, Microsoft, Meta im Fokus
Top News
Strategy-Aktie im Plus: Strategy schafft es aus den roten Zahlen Strategy-Aktie im Plus: Strategy schafft es aus den roten Zahlen
Apple-Aktie steigt: Apple-Bilanz lässt Anleger jubeln Apple-Aktie steigt: Apple-Bilanz lässt Anleger jubeln
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novo Nordisk Aktie

Handeln
Aktien-Sparplan anlegen
41,37 EUR -3,03 EUR -6,81 %
BMN
42,45 EUR -1,51 EUR -3,44 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.193,42 Mrd. EUR

KGV27,53Div. Rendite1,83%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EU6F

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINDK0062498333

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNONOF

Novo Nordisk Aktien News

DatumMeistgelesen
GlobeNewswireNovo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in th
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireTrading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
GlobeNewswireNovo Nordisk A/S - Articles of Association, April 2024
GlobeNewswireNovo Nordisk A/S – Reduction of the share capital
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
GlobeNewswireNovo Nordisk A/S - Articles of Association 2024
GlobeNewswireAwiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
GlobeNewswireHighlights to be presented at Novo Nordisk’s Capital Markets Day 2024
GlobeNewswireNovo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNotice for the Annual General Meeting of Novo Nordisk A/S
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.